CHICAGO — Moderna Therapeutics (MRNA) has already raised billions of dollars, pulled off the largest IPO in biotech history, and now carries a market valuation of more than $7 billion. Saturday, the messenger RNA “startup” made its debut at the American Society of Clinical Oncology annual meeting, showcasing for the first time some early data on a personalized cancer vaccine.

The vaccine, called mRNA-4157, was administered alone and in combination with Merck’s checkpoint inhibitor Keytruda without any serious side effects. The patients were injected with the customized vaccine after their solid tumors had been removed via surgery. Immune responses were detected and most remain in remission, suggesting the vaccine was helping the patient’s body recognize and attack the unique proteins found on tumor cells.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy